Figure 1
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
August 14, 2024 08:30 ET | Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
22157.jpg
Molecular Diagnostics for Neurodegenerative Diseases Technology Research Report 2024-2028 Featuring Synaps Dx, AgenT Biotech, Urvogelbio, Resonant, and Neurodex
August 01, 2024 04:46 ET | Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028" report has been added to ResearchAndMarkets.com's...
Vaccinex logo
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
July 31, 2024 09:00 ET | Vaccinex, Inc.
Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
22157.jpg
United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028
March 28, 2024 17:56 ET | Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
Orphai071eFINAL Soc Med.jpg
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
February 15, 2024 10:38 ET | OrphAI Therapeutics Inc.
GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
Logo.jpg
Neurodegenerative Disease Market Size To Reach USD 96.4 Billion By 2032 | DataHorizzon Research
February 12, 2024 07:10 ET | DataHorizzon Research
Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...
market-digits.jpg
Neurodegenerative Disease Market projected to reach USD 69.8 Billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030 - Claims by MarketDigits in its recent study Richmond, Nov. 28, 2023 (GLOBE NEWSWIRE) -- According to a research report "Neurodegenerative Disease Market, By Indication Type (Alzheimer's Disease, Huntington Disease, Multiple Sclerosis,...
sandoz-logo.jpg
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
September 26, 2023 01:15 ET | Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from...
22157.jpg
Neuroscience R&D Conference 2023: Unfolding the Recent Advancements in Preclinical and Translational Approaches Treating Neurodegenerative Disorders (London, United Kingdom - October 9-10, 2023)
August 18, 2023 04:13 ET | Research and Markets
Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.Unfolding the recent advancements in preclinical and...
Vaccinex logo
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023 08:00 ET | Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....